Paper32199724
Accelerating the development of innovative cellular therapy products for the treatment of cancer.
Stewart MD and 16 others. Cytotherapy, 2020. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Accelerating the development of innovative cellular therapy products for the treatment of cancer. Papers, record 32199724. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32199724
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Accelerating the development of innovative cellular therapy products for the treatment of cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell- and Tissue-Based Therapy | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Neoplasms | Major topic |
| Therapies, Investigational | Major topic |
| Child | |
| Combined Modality Therapy | |
| Humans | |
| Parents | |
| Patient Safety | |
| United States | |
| United States Food and Drug Administration |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42464296 | Advanced herbal self-assembled nanoplatforms: targeted, stimuli-responsive, and precision therapeutics for human diseases. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42464296 | PubMed |
| 40937560 | Ursolic acid: A natural pentacyclic triterpenoid with clinical promise in gynecological and breast cancers (Review). | Oncol Rep | 2025 | https://conductscience.org/library/papers/40937560 | PubMed |
| 38077331 | Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations. | Front Immunol | 2023 | https://conductscience.org/library/papers/38077331 | PubMed |
| 36329460 | Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells. | J Transl Med | 2022 | https://conductscience.org/library/papers/36329460 | PubMed |
| 35606815 | The future of cancer immunotherapy for brain tumors: a collaborative workshop. | J Transl Med | 2022 | https://conductscience.org/library/papers/35606815 | PubMed |
| 33833444 | Industrializing engineered autologous T cells as medicines for solid tumours. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33833444 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32199724
GET https://conductscience.org/api/papers/v1/32199724/authors